<DOC>
	<DOC>NCT00396799</DOC>
	<brief_summary>The primary objective is to evaluate the bioequivalence between bazedoxifene/conjugated estrogens tablets produced using the current manufacturing process to bazedoxifene/conjugated estrogens tablets produced using a new manufacturing process</brief_summary>
	<brief_title>Bioequivalence Study Of Bazedoxifene/Conjugated Estrogen Tablets In Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Estrogens, Conjugated (USP)</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Bazedoxifene</mesh_term>
	<criteria>Inclusion Criteria Healthy, postmenopausal women aged 35 to 70 years and weighing at least 50 kg (approx. 110 lbs). At least 6 months of spontaneous amenorrhea (with folliclestimulating hormone levels of 39 mIU/mL or greater). Nonsmoker or smoker of fewer than 10 cigarettes per day, with ability to abstain for 5 days. Exclusion Criteria Women with amenorrhea starting after 54 years of age. A history or active presence of clinically important medical diseases. Use of oral estrogen, progestin, androgen, or SERMcontaining drug products within 30 days before receiving study drug.</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2007</verification_date>
</DOC>